ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) updated its investors and all the other stakeholders about some of the recent and upcoming major activities. In addition to this, ZIOPHARM also announced financial results for the year 2015. The biggest highlight of the results was its net loss that reduced to $0.07 per share or $9.5 million in 4Q2015.

Other Financial And Non-Financial Highlights

In 4Q2014, ZIOPHARM reported a total net loss of $0.09 per share or $10.4 million. The Research & Development expenses for the quarter were $8.1 million, unchanged from the R&D expenses reported by the company during the same period in 2014. The R&D cost in 2015 comprised of CAR-T programs worth $4.5 million, employee related expenses worth $1.3 million, gene therapy programs worth $1.6 million and other expenses worth $0.7 million.

The general and administrative expenses for 4Q2015 were $3.3 million as compared to G&A expenses of $2.9 million in 4Q2014. The primary reason for this slight growth in G&A expenses was but employee-related expenses, such as non-cash equity compensation worth $0.4 million.

At the end of the December quarter, ZIOPHARM had about $140.7 million cash and cash equivalents. It has planned a series of activities to be carried out throughout 2016 and 2017 to expand the business and add more value to investors funds than all the previous years and hopes that the current cash and cash equivalents will be good enough for this initiative.

The senior management team is quite happy with the way ZIOPHARM has bounced back in the market amid volatile market situation. Going forward, it will look forward to attaining profitability and sustainable position to ensure more and more shareholders can have faith in company’s capabilities. All the details about upcoming financial and nonfinancial activities will be announced from time to time and shared with ZIOPHARM shareholders on a regular basis.